7 recruiting, 1 active not recruiting. 8 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 7, Active not recruiting 1 |
| Phase 1 | 6 | Recruiting 6 |
Follow I-DXd: new trials by email Literature Review of I-DXd trials Research Report on I-DXd
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01) Ifinatamab Deruxtecan - Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 134 | 2026-07-06 | 2026-10-30 |
| A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F) I-DXd, Rescue Medication - Oesophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 60 | 2026-03-27 | 2026-11-10 |
| A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) Gocatamig, I-DXd, Atezolizumab - Small Cell Lung Cancer Extensive Stage | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 170 | 2026-01-29 | 2026-11-09 |
| Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) Pembrolizumab, I-DXd, Leucovorin - Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 298 | 2025-07-30 | 2026-11-13 |
| Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) R-DXD, I-DXD, Docetaxel - Lung Neoplasm | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 144 | 2025-05-28 | 2026-11-13 |
| A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01) Raludotatug Deruxtecan, Ifinatamab Deruxtecan, Docetetaxel - Carcinoma, Non-Small-Cell Lung | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 96 | 2025-05-13 | 2026-11-06 |
| A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) Ifinatamab deruxtecan, Atezolizumab, Carboplatin - Extensive Stage-small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Daiichi Sankyo | 123 | 2024-07-22 | 2026-10-01 |
| A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) Ifinatamab deruxtecan - Recurrent or Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Daiichi Sankyo | 680 | 2024-04-10 | 2026-10-26 |
Esophageal Squamous Cell Carcinoma (2) · Adenocarcinoma Of Esophagus (1) · Biliary Tract Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Recurrence (1)
Merck Sharp & Dohme LLC (6) · Daiichi Sankyo (2)
United States (8) · Chile (6) · Spain (6) · France (5) · Germany (5) · Italy (5) · Turkey (Türkiye) (5) · China (4) · Israel (4) · Japan (4) · Poland (4) · South Korea (4) · Brazil (3) · Czechia (3) · Greece (3)
2023 (2), 2025 (2)